Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 05:00PM GMT
Release Date Price: $47.68 (+2.34%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior analysts here at JPMorgan. I'm joined by my team, Malcolm Kono, and Priyanka Grover. Our next presenting company is Apellis. And presenting on behalf of the company, we have CEO, Cedric Francois. Cedric?

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you very much. thank you for inviting us. So good to do this in person again. So in the next 20 minutes, I'm going to take you through the story around that pennies what we have been doing in the recent past and what we have to look forward to in the next year.

These are our forward-looking statements. You can also find our SEC filings online. So we have a lot to look forward to. The next month, we have our PDUFA and geographic atrophy on February 26 and with the opportunity to deliver the first ever treatment for geographic atrophy, one of the leading causes of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot